Core Viewpoint - The company aims to enhance operational quality, optimize governance structure, strengthen technological empowerment, and actively return to investors, thereby achieving high-quality development and sustainable growth by implementing the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan for 2025 [1][12]. Group 1: Operational Quality Enhancement - The company focuses on "guarding human health" and is a high-tech enterprise deeply engaged in the new drug research and development industry chain [1]. - The company achieved operating revenue of 627.53 million yuan, a year-on-year increase of 17.91%, and a net profit attributable to shareholders of 73.34 million yuan, a year-on-year increase of 41.57% [2]. - The gross profit margin reached 44.25%, an increase of 4.74 percentage points compared to the same period last year [2]. Group 2: Market and Industry Insights - The global drug research and development investment is projected to reach $147.7 billion in 2024, growing at an annual rate of 7.9%, and expected to exceed $200 billion by 2028 [3]. - The molecular building block industry plays a crucial role in drug development, with North America accounting for 35% of the global market share, Europe 27%, and Asia-Pacific 26% [3]. Group 3: Product Development and Innovation - The company has established a product library containing nearly one million molecular building blocks and scientific reagents, with over 140,000 types of products available [4]. - The company emphasizes research and development innovation, continuously enriching its product portfolio and introducing high-value, customized molecular building blocks and scientific reagents [5]. - The company has obtained 54 invention patents, 24 utility model patents, and 2 software copyrights, with 76 invention patents currently under application [6]. Group 4: Governance and Compliance - The company is enhancing its governance structure in accordance with relevant laws and regulations, ensuring that shareholders can fully exercise their rights [5][6]. - The board of directors has established specialized committees to ensure effective decision-making and oversight [6]. Group 5: Investor Relations and Market Confidence - The company plans to distribute a cash dividend of 9 yuan per 10 shares, totaling approximately 77.86 million yuan, which accounts for 66.31% of the net profit attributable to shareholders [11]. - The company has completed a stock buyback of 207,000 shares, amounting to 94.14 million yuan, to enhance market confidence [12]. - The company maintains open communication with investors through various channels, ensuring transparency and responsiveness to investor inquiries [12][13].